Skip to main content
. 2003 Jan 20;2003(1):CD002278. doi: 10.1002/14651858.CD002278

1.2. Analysis.

Comparison 1 Fluoride toothpaste versus placebo, Outcome 2 D(M)FT increment (prevented fraction) ‐ nearest to 3 years (53 trials).

D(M)FT increment (prevented fraction) ‐ nearest to 3 years (53 trials)
Study Prevented fraction 95% c.i.
Abrams 1980 15% (4% to 26%)
Andlaw 1975 18% (10% to 26%)
Blinkhorn 1983 30% (18% to 43%)
Brudevold 1966 22% (13% to 31%)
Buhe 1984 17% (11% to 23%)
Cahen 1982 15% (9% to 20%)
Di Maggio 1980 51% (45% to 56%)
Fogels 1979 12% (2% to 21%)
Gish 1966 14% (‐1% to 29%)
Glass 1978 25% (11% to 40%)
Glass 1983 28% (16% to 39%)
Hanachowicz 1984 26% (19% to 33%)
Hargreaves 1973 17% (‐3% to 38%)
Hargreaves 1973a 29% (14% to 4%)
Hargreaves 1973b 11% (‐4% to 26%)
Held 1968 93% (85% to 101%)
Held 1968a 40% (‐4% to 83%)
Held 1968b 59% (10% to 109%)
Hodge 1980 22% (14% to 30%)
Horowitz 1966 17% (6% to 27%)
Howat 1978 27% (17% to 37%)
Jackson 1967 10% (3% to 18%)
James 1967 11% (‐2% to 24%)
Kleber 1996 ‐2% (‐50% to 47%)
Koch 1967 35% (24% to 46%)
Koch 1967a 30% (17% to 43%)
Koch 1967b 30% (‐3% to 63%)
Koch 1967c 5% (‐14% to 24%)
Lind 1974 31% (23% to 38%)
Marthaler 1965 33% (20% to 45%)
Marthaler 1965a 16% (‐5% to 37%)
Marthaler 1974 33% (15% to 52%)
Mergele 1968 6% (‐5% to 18%)
Muhler 1955 34% (11% to 57%)
Muhler 1970 32% (16% to 49%)
Naylor 1967 8% (1% to 15%)
Naylor 1979 20% (12% to 27%)
Peterson 1967 14% (5% to 23%)
Peterson 1979 10% (‐7% to 26%)
Reed 1973 18% (8% to 28%)
Reed 1975 26% (10% to 41%)
Ringelberg 1979 15% (1% to 30%)
Rule 1984 24% (14% to 34%)
Slack 1967 ‐2% (‐14% to 11%)
Slack 1967a 4% (‐7% to 14%)
Thomas 1966 31% (15% to 47%)
Weisenstein 1972 15% (1% to 28%)
Zacherl 1970 35% (24% to 47%)
Zacherl 1970a 37% (29% to 46%)
Zacherl 1972 20% (6% to 34%)
Zacherl 1972a 21% (8% to 33%)
Zacherl 1973 35% (18% to 53%)
Zacherl 1981 31% (20% to 42%)
HHS Vulnerability Disclosure